QUANTUM-WILD: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB IN COMBINATION WITH CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN FLT3-ITD-NEGATIVE ACUTE MYELOID LEUKEMIA (AML)
EHA Library, Pau Montesinos,
4161654
A RANDOMIZED, OPEN LABEL, SINGLE-DOSE, 4-PERIOD, 4-TREATMENT CROSS-OVER STUDY TO EVALUATE THE PHARMACOKINETICS OF ORAL ARSENIC TRIOXIDE SOLUTION (SDK001) AND TO COMPARE TO INTRAVENOUS ARSENIC TRIOXIDE
EHA Library, Harry Gill,
4161664
COST-EFFECTIVENESS OF VENETOCLAX-OBINUTUZUMAB VS. VENETOCLAX-RITUXIMAB, VENETOCLAX-OBINUTUZUMAB-IBRUTINIB, AND CHEMOIMMUNOTHERAPY IN TREATMENT-NAÏVE FIT CLL PATIENTS WITHOUT TP53 ABERRATIONS
EHA Library, Lars Ehlers,
4161708
EFFECTS OF A 6-WEEK MINDFULNESS-BASED CANCER RECOVERY INTERVENTION ON ANXIETY, DEPRESSION, AND INSOMNIA AMONG HOSPITALIZED PATIENTS WITH HEMATOLOGIC NEOPLASMS: A PRE-EXPERIMENTAL STUDY
EHA Library, Jie Liu,
4162857